RxDoctor Payments Data

Masood Siddiquee, MD

Internal Medicine · Conyers, GANPI 1871551788

Payments from drug & device makers

$1,724in general payments, 2019–2025

Across 90 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$568
  • Johnson & Johnson$353
  • AstraZeneca$216
  • Pfizer$215
  • GSK$82
  • Merck$57
  • plus $232 from 10 others

What the payments were for

  • Food & beverage$1,724100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,724 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$78,793
Medicare patients
147
Services billed
934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$84,464
Xigduo XrDapaglifloz Propaned/Metformin59$71,265
RybelsusSemaglutide52$70,193
FarxigaDapagliflozin Propanediol38$53,628
JanuviaSitagliptin Phosphate27$37,680
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$35,895
EliquisApixaban24$31,449
LinzessLinaclotide14$22,299
ShingrixVaricella-Zoster Ge/As01b/Pf94$20,744
JardianceEmpagliflozin16$19,763
MounjaroTirzepatide11$14,092
XareltoRivaroxaban13$12,999
Tresiba Flextouch U-100Insulin Degludec17$10,596
BelsomraSuvorexant12$5,171
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf70$4,909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Shingrix$82$56,639126 claims
AstraZenecaFarxiga$216$53,62838 claims
MerckJanuvia, Belsomra$57$42,85139 claims
PfizerEliquis$215$31,44924 claims
Lilly USA, LLCMounjaro$56$14,09211 claims
Johnson & JohnsonXarelto$353$12,99913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Conyers

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →